Can I read Correction to: Review of Transthyretin Silencers, Stabilizers, and Fibril Removal Agents in the Treatment of Transthyretin Cardiac Amyloid on EtoBox?

Correction to: Review of Transthyretin Silencers, Stabilizers, and Fibril Removal Agents in the Treatment of Transthyretin Cardiac Amyloid by Hough, Augustus; Wearden, Jessica; de Almeida, Kristen; Kaiser, Stephanie is a Medicine article available to read on EtoBox.

What is Correction to: Review of Transthyretin Silencers, Stabilizers, and Fibril Removal Agents in the Treatment of Transthyretin Cardiac Amyloid about?

On page 2 of the original publication, in the section on TTR Silencers, dosing of patisiran in the APOLLO study was stated as being given every 3 months; this is inaccurate as patisiran was dosed every 3 weeks in the APOLLO study. The corrected sentence is presented below: "Patisiran, as an intravenous infusion every 3 weeks, also slowed functional decline versus placebo in the APOLLO study; however, in contrast to inotersen, 56% of patients had an improvement in functional outcomes from baseline [14]." Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Who reads Correction to: Review of Transthyretin Silencers, Stabilizers, and Fibril Removal Agents in the Treatment of Transthyretin Cardiac Amyloid?

Author

Hough, Augustus; Wearden, Jessica; de Almeida, Kristen; Kaiser, Stephanie

Publisher

Springer; Springer-Verlag; Current Science Inc.; Springer Science and Business Media LLC (ISSN 1523-3782)

Published

2020

Language

EN

Field

Medicine (Health Sciences)